The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | An update on BET inhibition in myelofibrosis: data presented at ASH 2025
In this video, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, provides a brief update on BET inhibition for the treatment of myelofibrosis (MF). Prof. Harrison highlights several studies presented at the ASH 2025 meeting, including PROMise (ISRCTN12451433) and MANIFEST (NCT02158858), that demonstrate the efficacy and tolerability of BET inhibitors in combination with JAK inhibitors. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
